(Circulation. 2000;101:1423.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From Nemours Cardiac Center, Alfred I. Dupont Hospital for Children, Wilmington, Del (R.D.M.); Childrens HospitalSan Diego, San Diego, Calif (E.C., K.S., M.A.); and Quest Diagnostics, Nichols Institute, San Juan Capistrano, Calif (J.C.N.).
Correspondence to Richard D. Mainwaring, MD, Alfred I. DuPont Hospital for Children, Nemours Cardiac Center, 1600 Rockland Road, PO Box 269, Wilmington, DE 19899. E-mail rmainwar{at}nemours.org
BackgroundTriiodothyronine (T3) supplementation may be a useful adjunct in the management of patients after cardiopulmonary bypass. Limited data are available regarding the use and pharmacokinetics of T3 in children. The present study was performed to evaluate T3 pharmacokinetics in a cohort of children undergoing the modified Fontan procedure.
Methods and ResultsA total of 28 patients were enrolled in this randomized, prospective study. The patients were divided into 4 groups: 1 group received a placebo and 3 groups received intravenous T3 at dosages of 0.4, 0.6, and 0.8 µg/kg, respectively. All 28 patients survived their operative procedures. Two patients developed low cardiac output, and 3 patients had pleural effusions. The median length of hospital stay was 7 days. The mean free T3 level was 316±67 pg/dL after then administration of a placebo. Patients who received T3 had mean peak free T3 levels of 972±88, 1351±299, and 1869±281 pg/dL for the dosages of 0.4, 0.6, and 0.8 µg/kg, respectively. The calculated half-life of T3 was 7 hours.
ConclusionsThe half-life of intravenous T3 in children is approximately one-third of that reported for adults. These results provide a framework for studying the efficacy of T3 supplementation in children undergoing open-heart surgery.
Key Words: Fontan procedure heart defects, congenital pediatrics cardiopulmonary bypass
This article has been cited by other articles:
![]() |
S. Ullah, L. Zabala, B. Watkins, and M. L Schmitz Cardiac organ donor management Perfusion, March 1, 2006; 21(2): 93 - 98. [Abstract] [PDF] |
||||
![]() |
G. J. Kahaly and W. H. Dillmann Thyroid Hormone Action in the Heart Endocr. Rev., August 1, 2005; 26(5): 704 - 728. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chowdhury, K. Ojamaa, V. A. Parnell, C. McMahon, C. P. Sison, and I. Klein A prospective randomized clinical study of thyroid hormone treatment after operations for complex congenital heart disease J. Thorac. Cardiovasc. Surg., November 1, 2001; 122(5): 1023 - 1025. [Full Text] [PDF] |
||||
![]() |
I. Klein and K. Ojamaa Thyroid Hormone and the Cardiovascular System N. Engl. J. Med., February 15, 2001; 344(7): 501 - 509. [Full Text] [PDF] |
||||
![]() |
K. Ojamaa, A. Kenessey, R. Shenoy, and I. Klein Thyroid hormone metabolism and cardiac gene expression after acute myocardial infarction in the rat Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1319 - E1324. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Portman, C. Fearneyhough, X.-H. Ning, B. W. Duncan, G. L. Rosenthal, and F. M. Lupinetti Triiodothyronine repletion in infants during cardiopulmonary bypass for congenital heart disease J. Thorac. Cardiovasc. Surg., September 1, 2000; 120(3): 604 - 608. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |